| |
Wednesday, May 14, 2025 | 11am ET / 8am PT Biotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now. 
|
|
Today’s Big NewsApr 30, 2025 |
| By Gabrielle Masson Worldwide venture financing for the sector experienced a downturn from $8.1 billion in the first quarter of 2024 to $6.5 billion in 2025’s most recent quarter, GlobalData said in an April 30 release. |
|
|
|
By Conor Hale GE HealthCare said that while sales are predicted to stay the same, it now expects shrinking profit margins and earnings, and less cash on hand. |
By Zoey Becker GSK says it has identified "mitigation options" to navigate potential U.S. pharmaceutical tariffs. |
By Andrea Park Once again, several members of Congress have come together to call for an end to the tax deductions that drugmakers receive for their direct-to-consumer advertising. |
|
Tuesday, May 6, 2025 | 9am ET / 6am PT This webinar will explore how to use AI-driven tools for timely data-driven decisions that are critical to securing approvals, expediting market entry and sustaining competitive strength. Register now. 
|
|
By Fraiser Kansteiner The FDA on Wednesday approved J&J’s nipocalimab under the brand name Imaavy as a new treatment for generalized myasthenia gravis. The green light will likely tee off a showdown between J&J and established myasthenia gravis players Argenx and UCB. |
By Darren Incorvaia Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 progressive multiple sclerosis trial, but the New York biotech is pointing to other measures from the study as reason to continue developing the asset. |
By Conor Hale The MJFF has worked with Verily for years to assemble public data exploring the relationships between Parkinson's disease, genetics, the immune system and metabolism. |
By Andrea Park A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some breast cancer patients. |
By Kevin Dunleavy Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice, Sanofi has closed a deal to sell a 50% controlling stake of its consumer health business Opella for 10 billion euros ($11.4 billion). |
By Nick Paul Taylor Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making the outlay, around half of which is upfront, to buy Regulus Therapeutics for a rare renal disease drug that is set to enter phase 3 in the third quarter. |
By Nick Paul Taylor Charles Barkley is going on the offense after seeing his weight rebound. The NBA Hall of Famer has signed on as GLP-1 celebrity ambassador for Ro, working with the telehealth company to document his attempts to lose the weight he regained after pausing GLP-1 treatment. |
By Zoey Becker The company is going up against Pfizer's popular Vyndaqel franchise in the ATTR-CM field and has so far tallied 2,072 prescriptions since launching Attruby in December. |
By Nick Paul Taylor Pink slips have followed the green light at Entrada Therapeutics. Weeks after the FDA lifted a more than two-year-long hold, the biotech has set out plans to reduce its workforce by 20% and prioritize its clinical Duchenne muscular dystrophy candidates and key preclinical programs. |
Fierce podcasts Don’t miss an episode |
| Two journalists, one name and a candid conversation—Angus Liu and Angus Chen talk cancer reporting, racial identity and being mistaken for each other. |
|
|---|
|
|
|
Tuesday, May 20, 2025 | 11am ET / 8am PT This webinar will feature industry experts discussing the power of combining biomedical data analysis with matched tissue and molecular samples. Register today to learn more. 
|
|
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
Whitepaper Is your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
